Food and Drug Administration (FDA), the most commonly reported side effects of these medications include nausea, diarrhea, vomiting, constipation, abdominal pain, headache, fatigue, indigestion, dizziness, bloating, belching, and flatulence
Lilly recently reported topline results from the ATTAIN-1 phase-3 trial evaluating orforglipron, a once-daily oral glucagon-like-peptide-1 (GLP-1) receptor agonist for adults with obesity or overweight without diabetes
Capuccio S, Scilletta S, La Rocca F, Miano N, Di Marco M, Bosco G, Di Giacomo Barbagallo F, Scicali R, Piro S, Di Pino A
Glp1r and Gcg mRNA transcripts have been detected in RNA isolated from mouse skin and, using immunocytochemistry, the GLP-1R protein has been localised to regions of the epidermis adjacent to hair follicles [13]
"Obesity is a chronic disease so we should treat it the same way as, say, high blood pressure, where you just take those drugs every single day for the rest of your life." Suzanne Rose, PhD, Executive Director of Research, Stamford Health If youre considering stopping the medication, its essential to work with your healthcare provider on a structured plan
